3223 completed, 1432 unknown, 1306 recruiting, 850 terminated. 3229 Phase 2, 1725 Phase 1, 1300 Not applicable, 688 Phase 3, 170 Phase 4.
Follow Adenocarcinoma: new trials by email Literature Review of Adenocarcinoma trials Research Report on Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma | Not applicable | Not yet recruiting | Jonsson Comprehensive Cancer Center | 100 | 2027-09-02 | 2026-10-19 |
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration RayAblation - Liver Tumors | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2027-04-01 | 2026-10-16 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 27 | 2027-02-01 | 2026-10-01 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy - Hepatitis B, Human Papilloma Virus | Phase 4 | Not yet recruiting | Eunice Dube | 2140 | 2027-01-30 | 2026-07-30 |
| Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) Radiation Therapy, Standard of Care Radiation Therapy, No Intervention - Breast Cancer | Phase 3 | Not yet recruiting | NRG Oncology | 5270 | 2027-01-30 | 2026-09-30 |
| A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) Ivonescimab, IP PTX - Phase II, Ivonescimab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2027-01-16 | 2026-08-27 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer Futibatinib, Ivosidenib + Capecitabine, Zanidatamab + Capecitabine - Biliary Tract Cancer (BTC) | Phase 3 | Not yet recruiting | UNICANCER | 990 | 2027-01-02 | 2026-08-04 |
| A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning. TheraSphere - Hepatocellular Carcinoma (HCC) | Not yet recruiting | Boston Scientific Corporation | 140 | 2027-01-01 | 2026-10-01 | |
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| Pilot Feasibility Study of a Dyadic Culinary Nutrition Intervention Cooking Healthy - Engaging Families (CHEF), Control - Neoplams, Prostate Cancer (Adenocarcinoma) | Not applicable | Not yet recruiting | University of Arizona | 40 | 2027-01-01 | 2026-07-14 |
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma Stereotactic body radiotherapy (SBRT) - Adenoid Cystic Carcinoma, Oligometastatic | Phase 2 | Not yet recruiting | All India Institute of Medical Sciences | 90 | 2026-12-20 | 2026-09-28 |
Showing 20 of 8225. Sign in to see all of them.
Carcinoma, Hepatocellular (3372) · Carcinoma, Renal Cell (1956) · Cholangiocarcinoma (778) · Carcinoma, Non-Small-Cell Lung (740) · Liver Neoplasms (597) · Breast Neoplasms (528) · Kidney Neoplasms (503) · Neoplasms (491) · Lung Neoplasms (458) · Pancreatic Neoplasms (430) · Melanoma (408) · Adenocarcinoma of Lung (404) · Neoplasm Metastasis (402) · Colorectal Neoplasms (384)
Neoplasms, Glandular and Epithelial (8192) · Neoplasms by Histologic Type (8187) · Carcinoma (8049) · Neoplasms (7734) · Neoplasms by Site (7239) · Digestive System Diseases (4343) · Digestive System Neoplasms (4286) · Liver Diseases (3396) · Liver Neoplasms (2849) · Urogenital Diseases (2391) · Urogenital Neoplasms (2330) · Female Urogenital Diseases and Pregnancy Complications (2272) · Female Urogenital Diseases (2259) · Male Urogenital Diseases (2186)
Sorafenib (323) · pembrolizumab (309) · Bevacizumab (299) · Nivolumab (271) · Gemcitabine (253) · lenvatinib (229) · Cisplatin (214) · Oxaliplatin (171) · Sunitinib (168) · Fluorouracil (163) · Radiotherapy (162) · Carboplatin (148) · Radiosurgery (140) · Magnetic Resonance Spectroscopy (135) · Capecitabine (129)
National Cancer Institute (NCI) (329) · Sun Yat-sen University (196) · M.D. Anderson Cancer Center (155) · Fudan University (93) · Pfizer (89) · Memorial Sloan Kettering Cancer Center (87) · Seoul National University Hospital (82) · Novartis Pharmaceuticals (79) · Shanghai Zhongshan Hospital (77) · Mayo Clinic (68) · Bayer (64) · Assistance Publique - Hôpitaux de Paris (56) · National Taiwan University Hospital (53) · University Health Network, Toronto (52) · Alliance for Clinical Trials in Oncology (51)
United States (3409) · China (1846) · France (724) · South Korea (554) · Italy (552) · Canada (482) · Spain (467) · Germany (451) · United Kingdom (427) · Taiwan (408) · Australia (308) · Netherlands (276) · Japan (262) · Belgium (260) · Poland (189)
Ming Shi, MD (23) · Jeong Min Lee, MD (14) · Tim F Greten, M.D. (13)
PMID 37146227, PMID 40812353, PMID 12049862, PMID 27238653, PMID 28410911, PMID 29433850, PMID 11981766, PMID 20375404, PMID 12540794, PMID 18650514, PMID 19192962, PMID 19095497, PMID 22551107, PMID 25577718, PMID 29628281, PMID 29875066, PMID 30207593, PMID 32402160, PMID 33526329, PMID 34143971, PMID 36852452, PMID 12091661, PMID 16757203, PMID 19097774, PMID 21374666, PMID 27932229, PMID 29471013, PMID 31401903, PMID 32499241, PMID 32557715, PMID 32716739, PMID 33058158, PMID 33538338, PMID 34905388, PMID 36410913, PMID 37097003, PMID 39462179, PMID 14667750, PMID 17960615, PMID 19766639, PMID 21612974, PMID 22980441, PMID 23964934, PMID 26361969, PMID 26702763, PMID 26706103, PMID 27279544, PMID 28434648, PMID 30998813, PMID 31070690
2023 (61), 2016 (45), 2018 (39), 2019 (37), U10CA032102 (37), P30CA033572 (35), 2025 (31), 2015 (28), P30CA016672 (28), U10CA031946 (27), 2017 (26), P30CA015083 (23), 2014 (22), P30CA043703 (22), P30CA060553 (21)